KR100872807B1 - 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법 - Google Patents

누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법 Download PDF

Info

Publication number
KR100872807B1
KR100872807B1 KR1020037010127A KR20037010127A KR100872807B1 KR 100872807 B1 KR100872807 B1 KR 100872807B1 KR 1020037010127 A KR1020037010127 A KR 1020037010127A KR 20037010127 A KR20037010127 A KR 20037010127A KR 100872807 B1 KR100872807 B1 KR 100872807B1
Authority
KR
South Korea
Prior art keywords
delete delete
polypeptide
nublastin
variant
nbn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020037010127A
Other languages
English (en)
Korean (ko)
Other versions
KR20030074766A (ko
Inventor
샤디나더블유.와이.
페핀스키알블레이크
보르잭-스조딘폴라앤
밀러스테판에스.
로소만도앤쏘니
Original Assignee
바이오겐 아이덱 엠에이 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오겐 아이덱 엠에이 인코포레이티드 filed Critical 바이오겐 아이덱 엠에이 인코포레이티드
Publication of KR20030074766A publication Critical patent/KR20030074766A/ko
Application granted granted Critical
Publication of KR100872807B1 publication Critical patent/KR100872807B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
KR1020037010127A 2001-02-01 2002-01-25 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법 Expired - Fee Related KR100872807B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26607101P 2001-02-01 2001-02-01
US60/266,071 2001-02-01
PCT/US2002/002319 WO2002060929A2 (en) 2001-02-01 2002-01-25 Polymer conjugates of neublastin and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020087022638A Division KR100960063B1 (ko) 2001-02-01 2002-01-25 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20030074766A KR20030074766A (ko) 2003-09-19
KR100872807B1 true KR100872807B1 (ko) 2008-12-09

Family

ID=23013042

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020037010127A Expired - Fee Related KR100872807B1 (ko) 2001-02-01 2002-01-25 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법
KR1020087022638A Expired - Fee Related KR100960063B1 (ko) 2001-02-01 2002-01-25 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020087022638A Expired - Fee Related KR100960063B1 (ko) 2001-02-01 2002-01-25 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법

Country Status (35)

Country Link
EP (2) EP1862475A1 (https=)
JP (2) JP4259868B2 (https=)
KR (2) KR100872807B1 (https=)
CN (1) CN1500095B (https=)
AR (1) AR035077A1 (https=)
AT (1) ATE365748T1 (https=)
AU (1) AU2002247037B2 (https=)
BG (1) BG66393B1 (https=)
BR (1) BR0206852A (https=)
CA (1) CA2436407C (https=)
CY (1) CY1106886T1 (https=)
CZ (1) CZ20032080A3 (https=)
DE (1) DE60220879T2 (https=)
DK (1) DK1355936T3 (https=)
EA (1) EA009771B1 (https=)
EE (1) EE05537B1 (https=)
ES (1) ES2289091T3 (https=)
GE (1) GEP20063916B (https=)
HU (1) HU228973B1 (https=)
IL (2) IL156941A0 (https=)
IS (1) IS2867B (https=)
MX (1) MXPA03006805A (https=)
MY (1) MY143685A (https=)
NO (1) NO332150B1 (https=)
NZ (1) NZ527863A (https=)
PL (1) PL211162B1 (https=)
PT (1) PT1355936E (https=)
RS (1) RS50857B (https=)
SG (1) SG149685A1 (https=)
SI (1) SI1355936T1 (https=)
SK (1) SK288123B6 (https=)
TR (1) TR200301208T2 (https=)
UA (2) UA100967C2 (https=)
WO (1) WO2002060929A2 (https=)
ZA (1) ZA200305733B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100960063B1 (ko) * 2001-02-01 2010-05-31 바이오겐 아이덱 엠에이 인코포레이티드 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7442370B2 (en) 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
CN1525866B (zh) * 2001-03-28 2013-05-29 比奥根艾迪克Ma公司 神经胚活素多肽的治疗作用
PT3025726T (pt) * 2002-01-18 2020-01-09 Biogen Ma Inc Compostos do polímero polialquileno e utilizações dos mesmos
EA008743B1 (ru) * 2003-01-31 2007-08-31 Байоджен Айдек Ма Инк. Полимерные конъюгаты мутантного неубластина
WO2004094592A2 (en) 2003-04-18 2004-11-04 Biogen Idec Ma Inc. Polymer-conjugated glycosylated neublastin
NZ544263A (en) 2003-06-10 2009-04-30 Nsgene As Improved secretion of neublastin
US7598059B2 (en) 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
CA2577690C (en) * 2004-08-19 2013-08-06 Biogen Idec Ma Inc. Refolding transforming growth factor beta family proteins
DK1786454T3 (da) 2004-08-19 2010-09-06 Biogen Idec Inc Neublastinvarianter
TWI501774B (zh) 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
EP2142205B1 (en) * 2007-05-01 2014-04-02 Biogen Idec MA Inc. Neublastin peptides for use in increasing vascularisation in tissue with impaired blood flow
HUE035685T2 (en) * 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography
RU2488635C1 (ru) * 2012-03-22 2013-07-27 Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО Первый МГМУ им. И.М. Сеченова Минздравсоцразвития Способ получения рекомбинантного антиангиогенного полипептида

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043813A1 (en) * 1998-02-27 1999-09-02 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
WO2000034475A2 (en) * 1998-12-09 2000-06-15 Amgen Inc. Grnf4, a gdnf-related neurotrophic factor
DK1355936T3 (da) * 2001-02-01 2007-10-29 Biogen Idec Inc Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999043813A1 (en) * 1998-02-27 1999-09-02 Regeneron Pharmaceuticals, Inc. Modified ciliary neurotrophic factor, method of making and methods of use thereof
WO2000001815A2 (en) * 1998-07-06 2000-01-13 Nsgene A/S Neurotrophic factors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100960063B1 (ko) * 2001-02-01 2010-05-31 바이오겐 아이덱 엠에이 인코포레이티드 누블라스틴의 중합체 컨쥬게이트 및 이의 사용 방법

Also Published As

Publication number Publication date
KR20080098662A (ko) 2008-11-11
SG149685A1 (en) 2009-02-27
EP1355936B1 (en) 2007-06-27
CZ20032080A3 (cs) 2003-10-15
HK1057759A1 (en) 2004-04-16
DE60220879T2 (de) 2008-03-06
EA009771B1 (ru) 2008-04-28
IL156941A (en) 2008-11-03
GEP20063916B (en) 2006-09-11
EP1862475A1 (en) 2007-12-05
JP2009039135A (ja) 2009-02-26
SK9712003A3 (en) 2004-01-08
PT1355936E (pt) 2007-09-28
KR100960063B1 (ko) 2010-05-31
UA82983C2 (ru) 2008-06-10
NO20033441L (no) 2003-10-01
UA100967C2 (ru) 2013-02-25
WO2002060929A2 (en) 2002-08-08
SI1355936T1 (sl) 2007-12-31
AR035077A1 (es) 2004-04-14
AU2002247037B2 (en) 2007-08-16
NZ527863A (en) 2006-09-29
HUP0500637A2 (hu) 2005-09-28
JP2005503763A (ja) 2005-02-10
WO2002060929A3 (en) 2003-03-06
PL211162B1 (pl) 2012-04-30
IL156941A0 (en) 2004-02-08
NO332150B1 (no) 2012-07-09
CA2436407C (en) 2011-08-30
YU61003A (sh) 2006-05-25
MXPA03006805A (es) 2003-11-13
EP1355936A2 (en) 2003-10-29
KR20030074766A (ko) 2003-09-19
CN1500095A (zh) 2004-05-26
HUP0500637A3 (en) 2010-01-28
CN1500095B (zh) 2010-06-16
CY1106886T1 (el) 2012-09-26
MY143685A (en) 2011-06-30
BG108111A (bg) 2004-12-30
SK288123B6 (sk) 2013-09-03
JP4423338B2 (ja) 2010-03-03
JP4259868B2 (ja) 2009-04-30
NO20033441D0 (no) 2003-08-01
BR0206852A (pt) 2005-05-03
RS50857B (sr) 2010-08-31
DE60220879D1 (de) 2007-08-09
ZA200305733B (en) 2005-02-23
IS6879A (is) 2003-07-17
ES2289091T3 (es) 2008-02-01
IS2867B (is) 2014-02-15
EE05537B1 (et) 2012-04-16
DK1355936T3 (da) 2007-10-29
PL372101A1 (en) 2005-07-11
TR200301208T2 (tr) 2005-05-23
BG66393B1 (bg) 2013-11-29
HU228973B1 (en) 2013-07-29
EE200300355A (et) 2003-10-15
EA200300852A1 (ru) 2004-06-24
ATE365748T1 (de) 2007-07-15
CA2436407A1 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
JP4423338B2 (ja) ニューブラスチンのポリマー結合体および同様の使用方法。
US8119114B2 (en) Polymer conjugates of mutated neublastin
AU2002247037A1 (en) Polymer conjugates of neublastin and methods of using same
RS61003B1 (sr) Postupak za kontrolu koncentracije hi u toku ostatka
KR101293805B1 (ko) 돌연변이된 뉴블라스틴의 중합체 컨주게이트
HK1057759B (en) Polymer conjugates of neublastin and methods of using same
HK1115142A (en) Polymer conjugates of neublastin and methods of using same
HK1156051A (en) Polymer conjugates of mutated neublastin
HK1085663B (en) Mutated neublastin

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

A107 Divisional application of patent
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20121123

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20131122

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20141121

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

R17-X000 Change to representative recorded

St.27 status event code: A-5-5-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20151203

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20151203

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000